Join the Definitive TPD Forum 2026: Advancing the Future of Targeted Protein Degradation
With 6 tracks spanning Academic Frontiers, Discovery, Preclinical Development, Translational and Clinical Development, Latest Tools & Technology and the Future of Induced Proximity, this is your one-stop TPD shop to get up to speed with the latest platform technologies, accelerate your R&D pipelines, validate novel ligases, and achieve clinical success for the next wave of proximity-based drugs.
Everyone who is anyone in the TPD field is gathering once again under one roof. With 350+ attendees across academia, start‑ups, biotechs, pharma, and solution providers, this meeting gives you direct access to the full TPD ecosystem. Get ready for proximity to leaders like Arvinas, Nurix Therapeutics, Monte Rosa Therapeutics, and more alongside pioneers unveiling novel platforms poised to transform the field.
Whether this is your first or ninth time attending this forum, we are proud to once again bring together this community to help tackle the challenges that shape your decisions, ensure you’re equipped to capture the tremendous opportunity TPD holds, and forge partnerships that will help you help patients with urgent unmet needs.
Brand New Companies for 2026
Key Speakers & Content Tracks
Discovery Track
This track will showcase novel cutting-edge platforms designed to unlock novel, previously undruggable targets, supported by rich in vitro and cell-based assay data. Attendees will gain a comprehensive view of the next wave of degraders and actionable insights into accelerating discovery.
Speaking Companies Include:
Pre-Clinical Development Track
This track will highlight the most promising degrader candidates advancing through in vivo validation and lead optimization across oncology, inflammatory and CNS indications.
Speaking Companies Include:
Translational & Clinical Development Track
This track will cover the latest translational and clinical data across degraders targeting oncology, autoimmune and CNS indications. Talks will cover how a wide breadth of mechanisms from PROTACs to DACs and AUTOTACs– are showing meaningful patient outcomes and trailblazing the way for TPD.
Speaking Companies Include:
Explore the 2026 Preliminary Agenda
Explore tracks spanning Academic Frontiers, Discovery, Preclinical Development, Translational and Clinical Development, Latest Tools & Technology and the Future of Induced Proximity.
Partner With Us
Position yourself alongside as the leading solution provider to ensure your brand is at the heart of TPD biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.